Persistent antibody positivity and gastrointestinal symptoms predicted progression of potential celiac disease to celiac disease
- PMID: 40288915
- DOI: 10.1016/j.dld.2025.04.004
Persistent antibody positivity and gastrointestinal symptoms predicted progression of potential celiac disease to celiac disease
Abstract
Background: The natural history of potential celiac disease is poorly defined.
Aims: To study factors predicting progression of potential celiac disease to overt celiac disease.
Methods: Medical data were collected from patients with potential celiac disease defined as positive tissue transglutaminase and/or endomysial autoantibodies without diagnostic duodenal villous atrophy.
Results: Of 158 patients with potential celiac disease (61 % women, median age 16 years, range 1-81 years), follow-up data were available for 128. The median follow-up time in patients not receiving a diagnosis was 14.6 years, and the median time until celiac disease diagnosis was 2.1 years. Serology normalized spontaneously in 38 %, while 61 % remained seropositive and 2 % began a gluten-free diet. Seventy-three patients underwent repeat endoscopy and 63 % of them received a celiac disease diagnosis. Those with later celiac disease diagnosis reported symptoms more often (84 % vs. 62 % p = 0.020) and were less frequently screen-detected (23 % vs. 52 %, p = 0.004) at their first endoscopy. During follow-up, they experienced persistent gastrointestinal symptoms more often (54 % vs. 27 %, p = 0.006) and remained seropositive (50 % vs. 16 %, p = 0.018).
Conclusion: During long-term follow-up, 63 % of the patients undergoing repeat endoscopy developed celiac disease. Predictive factors included baseline symptoms and persistence of gastrointestinal symptoms and sustained seropositivity.
Keywords: Gluten-free; Histology; Prognosis; Seropositivity.
Copyright © 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Conflict of interest LK received personal lecture fees from the Finnish Celiac Society and a travel grant from Takeda. KKu has received personal lecture fees from the Finnish Celiac Society, Columbia University and Thermo Fisher Scientific, and consulting fees from Takeda. Other authors report no conflict of interest.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
